TrialLancet (London, England)2021

Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.

Yu-Pei Chen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.